Univercells news

Univercells to participate in the State Visit to Japan of their Majesties the King and the Queen of the Belgians

Brussels, October 18, 2016

2016 marks the 150th anniversary of the signing of the still-standing bilateral trade accord between Belgium and Japan, initiating diplomatic ties between our two countries. To commemorate the occasion, King Philippe and Queen Mathilde of the Belgians will be accompanied by a delegation of academics and businesses on an official state visit to Japan from 9-15 October 2016.  Univercells’ CEO, Hugues Bultot has the honor to represent us and attend this dynamic event encouraging trade and cultural exchange. The Belgian royals and delegation will visit Japan at the invitation of Emperor Akihito.  Belgian Foreign Minister Didier Reynders (Francophone liberal) and Prime Minister of Belgium’s regional language community governments are also to be in attendance. The delegation will tour the country, making stops in Tokyo, Nagoya and Osaka.

State Visit to Japan 2016 logo - Univercells joins commercial delegation

Univercells will work locally during the visit with its fellow Japanese collaborator Takeda Pharmaceuticals since successful collaboration and equity investment in 2015, introducing them to the broader advantages of Belgian-Japanese commerce.  Takeda is a Japanese pharmaceutical company committed to the production and supply of vaccines to poor countries at low prices – nestling well into the mission and vision of Univercells to develop innovative biomanufacturing technologies able to significantly reduce vaccine cost of vaccine manufacturing.

Univercells joins Belgian State Visit to Japan

Takeda and Univercells representatives, Mr. Hitoshi Oinuma, Senior Vice President and Head of Japan, Vaccine Business Unit of Takeda Pharmaceutical, and Mr. Hugues Bultot, CEO of Univercells, participated in the official signing ceremony in presence of the Ministers, on October 12th 2016.   “Thanks to a powerful synergy between an innovative start-up with global objectives, and a global pharmaceutical player with open-minded interest for innovation, we hope to bring a significant improvement to global health in the near future!” conculded Hugues Bultot.